91 results
424B3
EX-31.2
CTCX
Carmell Therapeutics Corporation
16 Aug 24
Prospectus supplement
9:27am
) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit
424B3
EX-31.1
CTCX
Carmell Therapeutics Corporation
16 Aug 24
Prospectus supplement
9:27am
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee
DEF 14A
CTCX
Carmell Therapeutics Corporation
14 Jun 24
Definitive proxy
8:24am
Compensation
Security Ownership of Certain Beneficial Owners, Executive Officers, and Directors
Certain Relationships and Related Party Transactions
Audit … career at KPMG in an audit role. He graduated from Villanova University with a bachelor’s in accounting. We believe that Mr. Frisch is qualified to serve
424B3
br56ppveni0d
5 Jun 24
Prospectus supplement
6:06am
8-K
EX-10.1
3vk6o46s2tjswwt qp
4 Apr 24
Carmell Announces $3.0 Million Private Placement
5:28pm
8-K
EX-10.2
g8toffnhzdl3
4 Apr 24
Carmell Announces $3.0 Million Private Placement
5:28pm
8-K
EX-10.1
a90xua557m9qe78w
25 Mar 24
Entry into a Material Definitive Agreement
8:46pm
8-K
EX-99.1
gs6wm64
15 Nov 23
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors
9:54pm